-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Entering the end of the year, whether it is a local pharmaceutical company or a multinational company, the wave of turnover continues
.
On November 26, the results of the sixth batch of insulin special centralized procurement were released.
In this centralized procurement, 42 of 6 insulin products were planned to be selected.
The prices of the winning products were reduced by an average of 48%, involving domestic manufacturers such as Ganli Pharmaceutical and Dongyang Pharmaceutical, while imported manufacturers Mainly include Novo Nordisk, Sanofi and Eli Lilly
.
With the implementation of the centralized procurement results, the domestic insulin market will face tremendous changes
.
It is understood that after the release of the sixth batch of special insulin procurement results, the adjustment of personnel from many multinational pharmaceutical companies involved in the centralized procurement including Novo Nordisk and Sanofi has been accelerated
.
According to news at the end of November, Novo Nordisk, which won the bid for 7 products in the sixth batch of centralized procurement, with a drop of about 40%, plans to lay off 15-20% of its employees nationwide.
According to insiders, this This layoff is N+1 compensation
.
The specific notice shall be subject to the official announcement
.
The analysis believes that the products declared by Novo Nordisk this time are basically stuck in the line and won the bid, so some employees of the dedicated line may be laid off
.
Sanofi only selected two third-generation insulin varieties, insulin glulisine and insulin glargine, to be included in the collection.
Recently, there have been two successive news of personnel changes
.
One is that the cardiovascular and endocrine BU in a central province of Sanofi is preparing to lay off employees, and on the other side, employees on the CNS line have also received layoff emails
.
It is understood that although these two personnel changes have little to do with the insulin product line, the accompanying related product line changes are also coming soon
.
The industry believes that according to the principle of centralized procurement, after the drug is awarded the bid, the hospital will promise a certain amount of purchase, and the time for collection will be relatively greatly shortened
.
Therefore, as far as pharmaceutical companies are concerned, as long as the product enters the centralized procurement, whether it is winning or failing the bid, the role of the sales team will be weakened or even no longer needed, and more business and channel teams are needed
.
For drugs that have not won the bid in centralized procurement, pharmaceutical companies may lose most of the public hospital market, and the existence of the original sales team is no longer necessary
.
In addition to Sanofi and Novo Nordisk, there were also news of changes in the personnel of many multinational pharmaceutical companies before the centralized procurement
.
For example, on November 1, Ms.
Li Jinhui, general manager of Pfizer China’s current oncology and rare diseases business, was appointed as the general manager of the hospital’s emergency business department; on the same day, AstraZeneca’s vice president and county business department head Du Haochen Resign
.
It is understood that shortly after AstraZeneca’s announcement and county-level business adjustments, the county-level team issued a clear list of layoffs with a compensation plan of N+3; Ogalon was also exposed to layoffs and compensation policies for CVs in Guangdong, Sichuan and other regions.
N+1, while retaining double salary at the end of the year
.
In addition, on a global scale, many multinational pharmaceutical companies announced layoffs in November.
For example, on November 18, the Michigan-based pharmaceutical company Esperion announced that it would lay off about 170 employees in order to at least annually in 2021 and 2022.
Reduce the cost of 80 million U.
S.
dollars
.
On November 11, Lundbeck Pharmaceuticals also announced that it plans to remove 300 positions and use some of the saved funds to support the CGRP migraine drug Vyepti
.
In general, the resignation of multinational pharmaceutical company executives and the abolition of employees continued at the end of the year
.
In the domestic market, centralized drug procurement has been regularized, and the sixth round of centralized procurement is now in progress.
The seventh round of centralized procurement is also about to emerge.
The industry expects that the impact on multinational pharmaceutical companies will continue to be reflected
.
.
On November 26, the results of the sixth batch of insulin special centralized procurement were released.
In this centralized procurement, 42 of 6 insulin products were planned to be selected.
The prices of the winning products were reduced by an average of 48%, involving domestic manufacturers such as Ganli Pharmaceutical and Dongyang Pharmaceutical, while imported manufacturers Mainly include Novo Nordisk, Sanofi and Eli Lilly
.
With the implementation of the centralized procurement results, the domestic insulin market will face tremendous changes
.
It is understood that after the release of the sixth batch of special insulin procurement results, the adjustment of personnel from many multinational pharmaceutical companies involved in the centralized procurement including Novo Nordisk and Sanofi has been accelerated
.
According to news at the end of November, Novo Nordisk, which won the bid for 7 products in the sixth batch of centralized procurement, with a drop of about 40%, plans to lay off 15-20% of its employees nationwide.
According to insiders, this This layoff is N+1 compensation
.
The specific notice shall be subject to the official announcement
.
The analysis believes that the products declared by Novo Nordisk this time are basically stuck in the line and won the bid, so some employees of the dedicated line may be laid off
.
Sanofi only selected two third-generation insulin varieties, insulin glulisine and insulin glargine, to be included in the collection.
Recently, there have been two successive news of personnel changes
.
One is that the cardiovascular and endocrine BU in a central province of Sanofi is preparing to lay off employees, and on the other side, employees on the CNS line have also received layoff emails
.
It is understood that although these two personnel changes have little to do with the insulin product line, the accompanying related product line changes are also coming soon
.
The industry believes that according to the principle of centralized procurement, after the drug is awarded the bid, the hospital will promise a certain amount of purchase, and the time for collection will be relatively greatly shortened
.
Therefore, as far as pharmaceutical companies are concerned, as long as the product enters the centralized procurement, whether it is winning or failing the bid, the role of the sales team will be weakened or even no longer needed, and more business and channel teams are needed
.
For drugs that have not won the bid in centralized procurement, pharmaceutical companies may lose most of the public hospital market, and the existence of the original sales team is no longer necessary
.
In addition to Sanofi and Novo Nordisk, there were also news of changes in the personnel of many multinational pharmaceutical companies before the centralized procurement
.
For example, on November 1, Ms.
Li Jinhui, general manager of Pfizer China’s current oncology and rare diseases business, was appointed as the general manager of the hospital’s emergency business department; on the same day, AstraZeneca’s vice president and county business department head Du Haochen Resign
.
It is understood that shortly after AstraZeneca’s announcement and county-level business adjustments, the county-level team issued a clear list of layoffs with a compensation plan of N+3; Ogalon was also exposed to layoffs and compensation policies for CVs in Guangdong, Sichuan and other regions.
N+1, while retaining double salary at the end of the year
.
In addition, on a global scale, many multinational pharmaceutical companies announced layoffs in November.
For example, on November 18, the Michigan-based pharmaceutical company Esperion announced that it would lay off about 170 employees in order to at least annually in 2021 and 2022.
Reduce the cost of 80 million U.
S.
dollars
.
On November 11, Lundbeck Pharmaceuticals also announced that it plans to remove 300 positions and use some of the saved funds to support the CGRP migraine drug Vyepti
.
In general, the resignation of multinational pharmaceutical company executives and the abolition of employees continued at the end of the year
.
In the domestic market, centralized drug procurement has been regularized, and the sixth round of centralized procurement is now in progress.
The seventh round of centralized procurement is also about to emerge.
The industry expects that the impact on multinational pharmaceutical companies will continue to be reflected
.
